Number of pages: 100-120 | Report Format: PDF | Published date: 28 January, 2022
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021 to 2031
The global plasma-derived therapy market was pegged at ~US$ 25.4 billion in 2020 and is expected to witness a CAGR of ~6.2% during the forecast period.
Market Fundamentals
Plasma is the clear, straw-colored liquid portion of blood that remains after red blood cells (RBCs), white blood cells (WBCs), platelets and other cellular components are removed. It is the major component of blood and accounts for about 55% of blood content. Plasma contains water, salts, enzymes, antibodies and other proteins. Plasma is separated from the blood by a process known as plasmapheresis. Further, protein such as immunoglobulin, clotting factors, and albumin are derived from plasma.
Plasma derived therapy replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. It is utilized in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock & trauma, liver cirrhosis, and infectious diseases (tetanus, hepatitis, COVID-19 [still under clinical trials] and rabies).
[230230]
Market Dynamics
The global plasma derived therapy market is mainly driven by growing use of immunoglobulins in various therapeutic areas, and rising prevalence of life-threatening diseases such as immunodeficiency diseases and hemophilia. Awareness towards blood & plasma donation and increasing research & development activities are also playing a pivotal role in contributing to market growth globally. However, high cost of therapy and lack of reimbursement policies are likely to restrain market growth to a certain extent.
Market Ecosystem
The global plasma derived therapy market has been analyzed from four perspectives: Protein Derived, Application, End User, and Region.
Plasma Derived Therapy Market by Protein Derived
Based on protein derived, the market has been segmented into immunoglobulin, clotting factors, albumin and others. The immunoglobulin segment is expected to hold highest share during the forecast period owing to its benefits when used for treatment of various diseases. Immunoglobulin (also known as antibody) is used by the immune system of body to neutralize pathogens such as pathogenic bacteria and viruses. Therefore, immunoglobulins are derived from plasma of a recovered patient and are used to immunize patients of various autoimmune, infectious, and idiopathic diseases.
Plasma Derived Therapy Market by Application
[634232]
Based on application, the market has been segmented into infectious diseases, hereditary diseases and others. Hereditary diseases are expected to hold the highest share during the forecast period. Hereditary diseases that are treated by plasma-derived therapy include hemophilia, primary immunodeficiency disorder (PID), hereditary angioedema, von willebrand disease, among others. Infectious diseases treated by plasma derived therapy includes H1N1, COVID-19 (still under clinical trials), and hepatitis, among others. The growth of the hereditary diseases segment can be largely attributed to its high prevalence and growing awareness about its treatment by plasma derived therapy.
Plasma Derived Therapy Market by End User
Based on end-user, the market has been segmented into hospitals & clinics and research institutes. The hospitals & clinics segment is expected to dominate the plasma-derived therapy market with the highest share during the forecast period. The growth of the segment can be attributed to the frequent visits of patients to hospitals for diagnosis and treatment of various hematological and immunological disorders.
Plasma Derived Therapy Market by Region
Based on region, the global plasma-derived therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the plasma-derived therapy market, followed by Asia Pacific. The large share of North America in the global market can be attributed to early approval of plasma-derived products and the growing use of immunoglobulin in various therapeutic areas. For instance, since the detection of the first case of COVID-19 in the U.S. on January 19, 2020, the U.S. FDA has ramped up medical countermeasures to treat and prevent COVID-19. U.S. government has collaborated with multiple non-government organizations and biotech companies to develop hyper immune treatment products from convalescent plasma with an aim to boost the immune response of infected patients. Furthermore, advanced healthcare infrastructure for storing and maintaining high-quality source plasma has played a crucial role in the growth of this region in the global plasma derived therapy market.
Competitive Landscape
Some of the prominent players operating in the plasma derived therapy market includes:-
Strategic Developments
|
Report Attribute |
Details |
|
Historical Period |
2018 & 2019 |
|
Base year for estimation |
2020 |
|
Forecast period |
2021-2031 |
|
Market size in 2020 |
USD ~25.4 billion |
|
Growth Rate |
~6.2% |
|
Segments covered |
Protein Derived, Application, and End User |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
The global plasma-derived therapy market was estimated to clock at US$ ~25.4 billion in 2020
The global plasma derived therapy market is mainly driven by growing use of immunoglobulins in various therapeutic areas, and rising prevalence of life-threatening diseases such as immunodeficiency diseases and hemophilia. Awareness towards blood & plasma donation and increasing research & development activities are also playing a pivotal role in contributing to market growth globally.
Takeda Pharmaceutical Company Limited, Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB, Bio Products Laboratory U.S.A., Inc, China Biologic Products Holdings, Inc, Octapharma AG, Emergent BioSolutions Inc., among others
The growth rate of plasma-derived therapy market is CAGR of ~6.2% between 2021-2031
North America held the largest market share of the global plasma-derived therapy market in 2020
